Pfizer : Phase 2 Study Of Ponsegromab In Cancer Cachexia Meets Primary Endpoint
14/9 15:47
(RTTNews) - Pfizer Inc. (PFE) said Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia...